Research Paper Volume 13, Issue 14 pp 18978—18992

CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis

Exosomal miR-370 derived from BT-549-H promote BC metastasis. (A) Migration ability of BT-549 cells cocultured with BT-549-H cells or BT-549-H plus GW4869 treatment. Scale bar: 20 μm. (B) Invasion ability of BT-549 cells cocultured with BT-549-H cells or BT-549-H plus GW4869 treatment. Scale bar: 20 μm. (C) Morphology and size distribution of exosomes derived from BT-549 (BT-549-Exo) or BT-549-H (BT-549-H-Exo) cells, as determined by transmission electron microscopy, nanoparticle tracking analysis. (D) Expressions of exosomal markers CD63 and Tsg101, as detected by Western blotting. (E) Expressions of circFOXK2 and miR-370 in BT-549-Exo and BT-549-H-Exo. (F) Expression of miR-370 in BT-549 cells treated with BT-549-Exo and BT-549-H-Exo. (G) Exosomal miR-370 was taken up by recipient BT-549 cells, as determined by fluorescence staining assay. Scale bar: 20 μm. (H) Number of exosomes in BT-549 cells with overexpression or knockdown of circFOXK2. (I) Expression of exosomal miR-370 in BT-549 cells with overexpression or knockdown of circFOXK2. (J) Migration ability of BT-549 cells treated with exosomes containing miR-370 mimic or inhibitor. Scale bar: 20 μm. (K) Invasion ability of BT-549 cells treated with exosomes containing miR-370 mimic or inhibitor. Scale bar: 20 μm. Data were represented as mean ± SD. Each experimental group had at least three replicates. *p **p ***p

Figure 6. Exosomal miR-370 derived from BT-549-H promote BC metastasis. (A) Migration ability of BT-549 cells cocultured with BT-549-H cells or BT-549-H plus GW4869 treatment. Scale bar: 20 μm. (B) Invasion ability of BT-549 cells cocultured with BT-549-H cells or BT-549-H plus GW4869 treatment. Scale bar: 20 μm. (C) Morphology and size distribution of exosomes derived from BT-549 (BT-549-Exo) or BT-549-H (BT-549-H-Exo) cells, as determined by transmission electron microscopy, nanoparticle tracking analysis. (D) Expressions of exosomal markers CD63 and Tsg101, as detected by Western blotting. (E) Expressions of circFOXK2 and miR-370 in BT-549-Exo and BT-549-H-Exo. (F) Expression of miR-370 in BT-549 cells treated with BT-549-Exo and BT-549-H-Exo. (G) Exosomal miR-370 was taken up by recipient BT-549 cells, as determined by fluorescence staining assay. Scale bar: 20 μm. (H) Number of exosomes in BT-549 cells with overexpression or knockdown of circFOXK2. (I) Expression of exosomal miR-370 in BT-549 cells with overexpression or knockdown of circFOXK2. (J) Migration ability of BT-549 cells treated with exosomes containing miR-370 mimic or inhibitor. Scale bar: 20 μm. (K) Invasion ability of BT-549 cells treated with exosomes containing miR-370 mimic or inhibitor. Scale bar: 20 μm. Data were represented as mean ± SD. Each experimental group had at least three replicates. *p < 0.05, **p < 0.01, ***p < 0.001.